metaproterenol has been researched along with dobutamine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hagemann, K | 1 |
| Brown, L; Erdmann, E | 1 |
| Brandt, D; Klein, W | 1 |
| Bodem, G; Spannbrucker, N; Vogel, F | 1 |
| Del Barrio, AS; Garcia-Calonge, MA; Martinez, JA; Portillo, MP | 1 |
| Chalifour, LE; Dostanic, S; Servant, N; Wang, C | 2 |
2 review(s) available for metaproterenol and dobutamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Catecholamines in the therapy of chronic cardiac insufficiency].
Topics: Cardiotonic Agents; Catecholamines; Dobutamine; Dopamine; Epinephrine; Heart Failure; Humans; Isoproterenol; Metaproterenol; Myocardial Contraction; Norepinephrine; Practolol; Prenalterol; Receptors, Adrenergic, alpha; Vasoconstriction; Vasodilation | 1982 |
10 other study(ies) available for metaproterenol and dobutamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Atenolol poisoning].
Topics: Adult; Atenolol; Charcoal; Diazepam; Dobutamine; Dopamine; Drug Interactions; Female; Gastric Lavage; Humans; Metaproterenol; Suicide, Attempted | 1986 |
Concentration-response curves of positive inotropic agents before and after ouabain pretreatment.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cats; Dobutamine; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Female; Guinea Pigs; Histamine; Imidazoles; In Vitro Techniques; Male; Metaproterenol; Myocardial Contraction; Ouabain; Papillary Muscles; Phenylephrine; Stimulation, Chemical; Theophylline | 1985 |
[Sympathomimetics in intensive medicine].
Topics: Anaphylaxis; Critical Care; Dobutamine; Dopamine; Epinephrine; Heart Failure; Humans; Isoproterenol; Metaproterenol; Norepinephrine; Resuscitation; Sympathomimetics | 1981 |
Desensitization effect of in vivo treatment with metaproterenol on beta1, beta2 and beta3-adrenergic responsiveness in rat adipocytes.
Topics: Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; Animals; Cells, Cultured; Dobutamine; Ethanolamines; Fatty Acids, Nonesterified; Female; Kinetics; Lipolysis; Metaproterenol; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3; Time Factors | 1996 |
Chronic beta-adrenoreceptor stimulation in vivo decreased Bcl-2 and increased Bax expression but did not activate apoptotic pathways in mouse heart.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Cell Survival; Clusterin; DNA-Binding Proteins; Dobutamine; Drug Therapy, Combination; Early Growth Response Protein 1; Endoplasmic Reticulum Chaperone BiP; Gene Expression; Genes, bcl-2; Glycoproteins; Immediate-Early Proteins; Infusion Pumps; Isoproterenol; Metaproterenol; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocytes, Cardiac; Organ Size; Phenylephrine; Proto-Oncogene Proteins c-bcl-2; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; RNA; Transcription Factors | 2004 |
Egr-1 negatively regulates expression of the sodium-calcium exchanger-1 in cardiomyocytes in vitro and in vivo.
Topics: Animals; Calcium; Cells, Cultured; DNA-Binding Proteins; Dobutamine; Early Growth Response Protein 1; Immediate-Early Proteins; Infusion Pumps, Implantable; Isoproterenol; Male; Metaproterenol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocytes, Cardiac; Oligonucleotide Array Sequence Analysis; Phenylephrine; Propranolol; Sodium; Sodium-Calcium Exchanger; Stimulation, Chemical; Transcription Factors | 2005 |